NASDAQ:VTVT - vTv Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$1.57 -0.10 (-5.99 %)
(As of 06/25/2018 06:00 AM ET)
Previous Close$1.67
Today's Range$1.56 - $1.80
52-Week Range$0.65 - $8.40
Volume1.01 million shs
Average Volume717,390 shs
Market Capitalization$54.81 million
P/E Ratio-0.94
Dividend YieldN/A
Beta1.84
vTv Therapeutics logovTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The company's drug candidates comprise azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials for the treatment of Alzheimer's disease. Its drug candidates also include TTP399, an orally administered, liver-selective glucokinase activator that has completed Phase 2b clinical trials for the treatment of type 2 diabetes, as well as initiated Phase 1b/2 clinical trials for the treatment of type 1 diabetes; and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor, which has completed Phase II clinical trials for the treatment of type 2 diabetes. vTv Therapeutics Inc. has a license and research agreement with Calithera Biosciences, Inc. to develop and commercialize its hexokinase II inhibitors for therapeutic, prophylactic, preventative, or diagnostic use. The company was founded in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of vTv Therapeutics Holdings LLC.

Receive VTVT News and Ratings via Email

Sign-up to receive the latest news and ratings for VTVT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:VTVT
CUSIPN/A
Phone336-841-0300

Debt

Debt-to-Equity Ratio-0.09
Current Ratio0.35
Quick Ratio0.35

Price-To-Earnings

Trailing P/E Ratio-0.94
Forward P/E Ratio-1.43
P/E GrowthN/A

Sales & Book Value

Annual Sales$290,000.00
Price / Sales177.68
Cash FlowN/A
Price / CashN/A
Book Value($4.60) per share
Price / Book-0.34

Profitability

EPS (Most Recent Fiscal Year)($1.67)
Net Income$-16,140,000.00
Net Margins-639.83%
Return on EquityN/A
Return on Assets-58.08%

Miscellaneous

Employees56
Outstanding Shares32,820,000

The Truth About Cryptocurrencies

vTv Therapeutics (NASDAQ:VTVT) Frequently Asked Questions

What is vTv Therapeutics' stock symbol?

vTv Therapeutics trades on the NASDAQ under the ticker symbol "VTVT."

How were vTv Therapeutics' earnings last quarter?

vTv Therapeutics Inc (NASDAQ:VTVT) announced its earnings results on Tuesday, May, 15th. The biotechnology company reported ($0.30) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.26) by $0.04. The biotechnology company had revenue of $2.06 million for the quarter, compared to analyst estimates of $3.14 million. View vTv Therapeutics' Earnings History.

When is vTv Therapeutics' next earnings date?

vTv Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for vTv Therapeutics.

What price target have analysts set for VTVT?

8 Wall Street analysts have issued 1-year target prices for vTv Therapeutics' stock. Their forecasts range from $4.00 to $28.00. On average, they expect vTv Therapeutics' stock price to reach $14.7143 in the next twelve months. View Analyst Ratings for vTv Therapeutics.

Are investors shorting vTv Therapeutics?

vTv Therapeutics saw a decrease in short interest during the month of May. As of May 15th, there was short interest totalling 977,984 shares, a decrease of 32.3% from the April 30th total of 1,444,136 shares. Based on an average trading volume of 1,462,831 shares, the days-to-cover ratio is currently 0.7 days. Currently, 14.0% of the shares of the stock are short sold. View vTv Therapeutics' Current Options Chain.

Who are some of vTv Therapeutics' key competitors?

Who are vTv Therapeutics' key executives?

vTv Therapeutics' management team includes the folowing people:
  • Mr. Jeffrey B. Kindler, Exec. Chairman (Age 62)
  • Mr. Stephen L. Holcombe, Pres & CEO (Age 61)
  • Mr. Rudy C. Howard CPA, B.A., CPA, Exec. VP & CFO (Age 60)
  • Dr. Larry Douglas Altstiel, Exec. VP & Chief Medical Officer (Age 68)
  • Dr. Carmen Valcarce Ph.D., Chief Scientific Officer & Exec. VP

When did vTv Therapeutics IPO?

(VTVT) raised $125 million in an initial public offering (IPO) on Thursday, July 30th 2015. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Piper Jaffray and Stifel served as the underwriters for the IPO and Canaccord Genuity and Janney Montgomery Scott were co-managers.

Has vTv Therapeutics been receiving favorable news coverage?

Headlines about VTVT stock have trended somewhat positive on Monday, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. vTv Therapeutics earned a media sentiment score of 0.16 on Accern's scale. They also assigned news articles about the biotechnology company an impact score of 45.40 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Who are vTv Therapeutics' major shareholders?

vTv Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include MACANDREWS & FORBES INC. (79.80%), JPMorgan Chase & Co. (1.00%), C WorldWide Group Holding A S (0.30%) and Millennium Management LLC (0.29%). Company insiders that own vTv Therapeutics stock include Paul G Savas and Ronald O Perelman. View Institutional Ownership Trends for vTv Therapeutics.

Which institutional investors are buying vTv Therapeutics stock?

VTVT stock was acquired by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., C WorldWide Group Holding A S and Millennium Management LLC. Company insiders that have bought vTv Therapeutics stock in the last two years include Paul G Savas and Ronald O Perelman. View Insider Buying and Selling for vTv Therapeutics.

How do I buy shares of vTv Therapeutics?

Shares of VTVT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is vTv Therapeutics' stock price today?

One share of VTVT stock can currently be purchased for approximately $1.57.

How big of a company is vTv Therapeutics?

vTv Therapeutics has a market capitalization of $54.81 million and generates $290,000.00 in revenue each year. The biotechnology company earns $-16,140,000.00 in net income (profit) each year or ($1.67) on an earnings per share basis. vTv Therapeutics employs 56 workers across the globe.

How can I contact vTv Therapeutics?

vTv Therapeutics' mailing address is 4170 MENDENHALL OAKS PARKWAY, HIGH POINT NC, 27265. The biotechnology company can be reached via phone at 336-841-0300 or via email at [email protected]


MarketBeat Community Rating for vTv Therapeutics (VTVT)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  173 (Vote Outperform)
Underperform Votes:  163 (Vote Underperform)
Total Votes:  336
MarketBeat's community ratings are surveys of what our community members think about vTv Therapeutics and other stocks. Vote "Outperform" if you believe VTVT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VTVT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.